Targeting CDH17 with nanobody for immunotoxin delivery might be a good complementary strategy for GC patients who are not suitable for HER2 targeted therapy since higher percentage (66%) of GC patients express CDH17 protein. Here, ERBB2 is linked to gastric cancer.